The increasing challenge posed by multiresistant saprophytes in medical microbiology is strikingly demonstrated by the emergence of Burkholderia (formerly Pseudomonas) cepacia as an opportunist pathogen in immunocompromised patients, particularly individuals with chronic granulomatous disease and cystic fibrosis (CF). Best known previously as a phytopathogen and the cause of soft rot of onions, B. cepacia presents three major problems for the CF community: innate multiresistance to antimicrobial agents; person-to-person transmission of epidemic strains through nosocomial or social contacts; and ‘cepacia syndrome’, a fulminating fatal pneumonia, sometimes associated with septicaemia, that occurs in approximately 20% of colonised patients, including those with previously mild disease. Accumulated evidence to dispel earlier suggestions that the organism is avirulent and merely a marker of existing lung disease includes: case-controlled studies in CF patients; reports of serious infections in non-CF patients; in-vitro and in-vivo evidence that B. cepacia induces production of pro-inflammatory markers, including the major cytokine TNFα; and histopathological evidence that exposure of transgenic CF mice to B. cepacia results in pneumonia. By the early 1990s, the use of selective culture media and DNA-based bacterial fingerprinting confirmed suspicions of epidemic person-to-person spread of B. cepacia. This evidence provided scientific justification for draconian and controversial measures for infection control, in particular, segregation of B. cepacia-colonised patients during treatment at CF centres and their exclusion from social gatherings and national conferences. Recently, molecular analyses of type strains and clinical isolates have revealed that isolates identified previously as B. cepacia belong to at least three distinct species and have increased concern regarding the reliability of current laboratory detection and identification systems. Clarification of the taxonomy of B. cepacia-like organisms and the pathogenic potential of environmental isolates remains a high priority, particularly when the organism’s antifungal and degradative properties have created interest in its potential use as a biological control agent to improve crop yields and its use for the bioremediation of contaminated soils.
BeckmanW.,
LessieT. G. Response of Pseudomonas cepacia to β-lactam antibiotics: utilization of penicillin G as the carbon source. J Bacteriol1979; 140:1126–1128
YabuuchiE.,
KosakoY.,
OyaizuH. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol1992; 36:1251–1275
UrakamiT.,
Ito-YoshidaC.,
ArakiH.,
KajimaT.,
Suzuki, K-I., KomagataK. Transfer of Pseudomonas plantarii and Pseudomonas glumae to Burkholderia as Burkholderia spp. and description of Burkholderia vandii sp. nov. Int J Syst Bacteriol1994; 44:235–245
ZhaoN. X.,
QuC. F.,
WangE. T.,
ChenW. X. Phylogenetic evidence for the transfer of Pseudomonas cocovenenans (van Damme et al 1960) to the genus Burkholderia as Burkholderia cocovenenans (van Damme et al 1960) comb, nov. Int J Syst Bacteriol1995; 45:600–603
GillisM.,
VanT.,
BardinR. Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp. nov. for N2-fixing isolates from rice in Vietnam. Int J Syst Bacteriol1995; 45:274–289
PalleroniN. J.,
GenusI. Pseudomonas. In
KriegN. R.,
HoltJ. G.
(eds) Bergey’s Manual of systemic bacteriology vol 1 Baltimore: Williams and Wilkins Co; 1984141–159
WiseM. G.,
ShimketsL. J.,
McArthurJ. V. Genetic structure of a lotic population of Burkholderia (Pseudomonas) cepacia
. Appl Environ Microbiol1995; 61:1791–1798
FisherM. C.,
LiPumaJ. J.,
DasenS. E. Source of Pseudomonas cepacia: ribotyping of isolates from patients and from the environment. J Pediatr1993; 123:745–747
ButlerS. L.,
DohertyC. J.,
HughesJ. E.,
NelsonJ. W.,
GovanJ. R. W.Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard?. J Clin Microbiol1995; 33:1001–1004
MortensenJ. E.,
FisherM. C.,
LiPumaJ. J. Recovery of Pseudomonas cepacia and other Pseudomonas species from the environment. Infect Control Hosp Epidemiol1995; 16:30–32
HolmesA.,
NolanR.,
TaylorR. An epidemic of Burkholderia (Pseudomonas) cepacia affecting patients with cystic fibrosis and without cystic fibrosis. Lancet (in press)
McLoughlinT. J.,
QuinnJ. P.,
BettermannA.,
BooklandR.Pseudomonas cepacia suppression of sunflower wilt fungus and role of antifungal compounds in controlling the disease. Appl Environ Microbiol1992; 58:1760–1763
AokiM.,
UeharaK.,
TsujiK.,
OnoK.,
IijimaM. Large-scale culture and preservation methods of Pseudomonas cepacia B5 for biological control against bacterial wilt disease. Bioscience Biotech Biochem1993; 57:668–669
FolsomB. R.,
ChapmanP. J.,
PritchardP. H. Phenol and trichloroethylene degradation by Pseudomonas cepacia G4: kinetics and interactions between substrates. Appl Environ Microbiol1990; 56:1279–1285
KilbaneJ. J.,
ChatteijeeD. K.,
KamsJ. S.,
KelloggS. T.,
Chakra-bartyA. M. Biodegradation of 2,4,5-trichlorophenoxyacetic acid by pure culture of Pseudomonas cepacia
. Appl Environ Microbiol1982; 44:72–78
JohnsonW. M.,
TylerS. D.,
RozeeK. R. Linkage analysis of geographical and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol1994; 32:924–930
BassetD. C. J.,
StokesK. J.,
ThomasW. R. G. Wound infection with Pseudomonas multivorans: a water-borne contaminant of disinfectant solutions. Lancet1970; 1:1188–1191
JarvisW. R.,
OlsonD.,
TablanO.,
MartoneW. J. The epidemiology of nosocomial Pseudomonas cepacia infections: endemic infections. Eur J Epidemiol1987; 3:233–236
ThomassenM. J.,
DemkoC. A.,
KlingerJ. D.,
StemR. C.Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. Am Rev Respir Dis1985; 131:791–796
HobsonR.,
GouldI.,
GovanJ.Burkholderia (Pseudomonas) cepacia as a cause of brain abscesses secondary to chronic suppurative otitis media. Eur J Clin Microbiol Infect Dis1995; 14:908–911
LiPumaJ. J.,
FisherM. C.,
DasenS. E.,
MortensenJ. E.,
StullT. L. Ribotype stability of serial pulmonary isolates of Pseudomonas cepacia
. J Infect Dis1991; 164:133–136
SimpsonI. N.,
FinlayJ.,
WinstanleyD. J. Multi-resistance isolates possessing characteristics of both Burkholderia (Pseudomonas) cepacia and Burkholderia gladioli from patients with cystic fibrosis. J Antimicrob Chemother1994; 34:353–361
YohalemD. S.,
LorbeerJ. W. Multilocus isoenzyme diversity among strains of Pseudomonas cepacia isolated from decayed onions, soils, and clinical sources. Syst Appl Microbiol1994; 17:116–124
PittT. L.,
KaufmannM. E.,
PatelP. S.,
BengeL. C. A.,
GaskinS.,
LivermoreD. M. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol1996; 44:203–210
ScordilisG. E.,
ReeH.,
LessieT. G. Identification of transposable elements which activate gene expression in Pseudomonas cepacia
. J Bacterial1987; 169:8–13
SimmondsE. J.,
ConwayS. P.,
GhoneimA. T. M.,
RossH.,
Little-woodJ. M.Pseudomonas cepacia: a new pathogen in patients with cystic fibrosis referred to a large centre in the United Kingdom. Arch Dis Child1990; 65:874–877
GladmanG.,
ConnorP. J.,
WilliamsR. F.,
DavidT. J. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child1992; 67:192–195
SajjanU. S.,
CoreyM.,
KarmaliM. A.,
ForstnerJ. F. Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest1992; 89:648–656
TablanO. C.,
CarsonL. A.,
CusickL. B.,
BlandL. A.,
MartoneW. J.,
JarvisW. R. Laboratory proficiency test results on use of selective media for isolating Pseudomonas cepacia from simulated sputum specimens of patients with cystic fibrosis. J Clin Microbiol1987; 25:485–487
ThomassenM. J.,
DemkoC. A.,
DoershukC. F.,
StemR. C.,
KlingerJ. D.Pseudomonas cepacia: decrease in colonization in patients with cystic fibrosis. Am Rev Respir Dis1986; 134:669–671
LiPumaJ. J.,
DasenS. E.,
NielsonD. W.,
StemR. C.,
StullT. L. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet1990; 336:1094–1096
AndersonD. J.,
KuhnsJ. S.,
VasilM. L.,
GerdingD. N.,
JanoffE. N. DNA fingerprinting by pulsed field gel electrophoresis and ribotyping to distinguish Pseudomonas cepacia from a nosocomial outbreak. J Clin Microbiol1991; 29:648–649
SmithD. L.,
GumeryL. B.,
SmithE. G.,
StableforthD. E.,
KaufmannM. E.,
PittT. L. Epidemic of Pseudomonas cepacia in an adult cystic fibrosis unit: evidence of person-to-person transmission. J Clin Microbiol1993; 31:3017–3022
BingenE.,
BotzenhartK.,
ChabanonG. Epidemiology of pulmonary infections by Pseudomonas in patients with cystic fibrosis: a consensus report. French Cystic Fibrosis Association (AFLM), Paris1993
CorkillJ. E.,
SissonP. R.,
SmythA. Application of pyrolysis mass spectroscopy and SDS-PAGE in the study of the epidemiology of Pseudomonas cepacia in cystic fibrosis. J Med Microbiol1994; 41:106–111
PeguesD. A.,
CarsonL. A.,
TablanO. C. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr1994; 124:694–702
RyleyH. C.,
Millar-JonesL.,
PauliA.,
WeeksJ. Characterisation of Burkholderia cepacia from cystic fibrosis patients living in Wales by PCR ribotyping. J Med Microbiol1995; 43:436–441
SunL.,
Jiang, R-Z., SteinbachS. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nature Med1995; 1:661–666
WhitefordM. L.,
WilkinsonJ. D.,
McCollJ. H. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax1995; 50:1194–1198
HardyK. A.,
McGowanK. L.,
FisherM. C.,
SchidlowD. V.Pseudomonas cepacia in the hospital setting; lack of transmission between cystic fibrosis patients. J Pediatr1986; 109:51–54
SteinbachS.,
SunL.,
JiangR.-Z. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung-transplant recipients with cystic fibrosis. N Engl J Med1994; 331:981–987
MuhdiK.,
EdenboroughF. P.,
GumeryL. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax1996; 51:374–377
LewinL. O.,
ByardP. J.,
DavisP. B. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol1990; 43:125–131
SpeertD. P.,
BondM.,
WoodmanR. C.,
CurnutteJ. T. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J Infect Dis1994; 170:1524–1531
ButlerS. L.,
NelsonJ. W.,
PoxtonI. R.,
GovanJ. R. W. Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. FEMS Immunol Med Microbiol1994; 8:285–292
NelsonJ. W.,
ButlerS. L.,
BrownP. H.,
GreeningA. P.,
GovanJ. R. W. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. J Med Microbiol1993; 39:39–47
TipperJ. L.,
InghamE.,
CoveJ. H.,
ToddN. J.,
LittlewoodJ. M.,
KerrK. G. An immunofluorescent assay for determining the invasiveness of A549 cells by Burkholderia (Pseudomonas) cepacia
. 20th European Cystic Fibrosis Conference, Brussels1995P15
LandersP. D.,
TipperJ. L.,
RowbothamT. J.,
KerrK. G. Survival and multiplication of Burkholderia (Pseudomonas) cepacia within the free-living amoeba Acanthamoeba polyphaga
. 20th European Cystic Fibrosis Conference, Brussels1995P4
AronoffS. C.,
StemR. C. Serum IgG antibody to outer membrane antigens of Pseudomonas cepacia and Pseudomonas aeruginosa in cystic fibrosis. J Infect Dis1988; 157:934–940
LacyD. E.,
SmithA. W.,
StableforthD. E.,
SmithG.,
WellerP. H.,
BrownM. R. W. Serum IgG response to Burkholderia cepacia outer membrane antigens in cystic fibrosis: assessment of cross-reactivity with Pseudomonas aeruginosa
. FEMS Immunol Med Microbiol1995; 10:253–262
ParrT. R.,
MooreR. A.,
MooreL. V.,
HancockR. E. W. Role of porins in intrinsic antibiotic resistance of Pseudomonas cepacia
. Antimicrob Agents Chemother1987; 31:121–123
KonstanM. W.,
HilliardK. A.,
NorvellT. M.,
BergerM. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med1994; 150:448–454
ShawD. The regulation and biological activity of cell surface determinants in model opportunist aerobic and anaerobic bacterial pathogens. PhD thesis University of Edinburgh; 1995
ShawD.,
PoxtonI. R.,
GovanJ. R. W. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. FEMS Immunol Med Microbiol1995; 11:99–106
ShawD.,
PoxtonI. R.,
GovanJ. R. W. The induction of TNF by B. cepacia and P. aeruginosa lipopolysaccharide. 20th European Cystic Fibrosis Conference, Brussels199509
KiskaD. L.,
KerrA.,
JonesM. C. Accuracy of four commercial systems for identification of Burkholderia cepacia and other Gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol1996; 34:886–891
LeffL. G.,
KernanR. M.,
McArthurJ. V.,
ShimketsL. J. Identification of aquatic Burkholderia (Pseudomonas) cepacia by hybridization with species-specific rRNA gene probes. Appl Environ Microbiol1995; 61:1634–1636
UrsingJ. B.,
Rosello-MoraR. A.,
Garcia-ValdesE.,
LalucatJ. A pragmatic approach to the nomenclature of phenotypically similar genomic groups. Int J Syst Bacteriol1995; 45:604
ButlerS. L.,
NelsonJ. W.,
GovanJ. R. W. Cell surface characteristics of Pseudomonas cepacia isolates from patients with cystic fibrosis. XI International CF Congress, Dublin1992 Abstract TP8
SajjanU. S.,
ForstnerJ. F. Identification of the mucin-binding adhesin of Pseudomonas cepacia isolated from patients with cystic fibrosis. Infect Immun1992; 60:1434–1440
SajjanU. S.,
SunL.,
GoldsteinR.,
ForstnerJ. F. Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers. J Bacteriol1995; 177:1030–1038
NelsonJ. W.,
DohertyC. J.,
BrownP. H.,
GreeningA. P.,
KaufmannM. E.,
GovanJ. R. W.Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet1991; 338:1525
BurdgeD. R.,
NakielnaE. M.,
NobleM. A. Case-control and vector studies of nosocomial acquisition of Pseudomonas cepacia in adult patients with cystic fibrosis. Infect Control Hosp Epidemiol1993; 14:127–130
HutchinsonG. R.,
ParkerS.,
PryorJ. A. Home-use nebulizers: a potential primary source of Burkholderia cepacia and other colistin-resistant, Gram-negative bacteria in patients with cystic fibrosis. J Clin Microbiol1996; 34:584–587
HommaY.,
SatoZ.,
HirayamaF.,
KannoK.,
ShirahamaH.,
SuzuiT. Production of antibiotics by Pseudomonas cepacia as an agent for biological control of soilbom plant pathogens. Soil Biol Biochem1989; 21:723–728
FridlanderM.,
InbarJ.,
ChetI. Biological control of soilbome plant pathogens by a β-1,3-glucanase-producing Pseudomonas cepacia
. Soil Biol Biochem1993; 25:1211–1222
BhatM. A.,
TsudaM.,
HorikeK.,
NozakiM.,
VaidyanathanC. S.,
NakazawaT. Identification and characterization of a new plasmid carrying genes for degradation of 2,4-dichlorophe-noxyacetate from Pseudomonas cepacia CSV90. Appl Environ Microbiol1994; 60:307–312
KrummeM. L.,
TimmisK. N.,
DwyerD. F. Degradation of trichloroethylene by Pseudomonas cepacia G4 and the constitutive mutant strain G4 5223 PR1 in aquifer microcosms. Appl Environ Microbiol1993; 59:2746–2749
SmithJ. J.,
TravisS. M.,
GreenbergE. P.,
WelshM. J. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell1996; 85:229–236